- Home
- SLG vs ICUI Comparison
SLG vs ICUI Comparison
Compare SLG & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLG
- ICUI
- Stock Information
- Founded
- SLG 1980
- ICUI 1984
- Country
- SLG United States
- ICUI United States
- Employees
- SLG N/A
- ICUI N/A
- Industry
- SLG Real Estate Investment Trusts
- ICUI Medical/Dental Instruments
- Sector
- SLG Real Estate
- ICUI Health Care
- Exchange
- SLG Nasdaq
- ICUI Nasdaq
- Market Cap
- SLG 4.1B
- ICUI 3.8B
- IPO Year
- SLG 1997
- ICUI 1992
- Fundamental
- Price
- SLG $55.59
- ICUI $140.19
- Analyst Decision
- SLG Hold
- ICUI Buy
- Analyst Count
- SLG 15
- ICUI 4
- Target Price
- SLG $71.00
- ICUI $199.67
- AVG Volume (30 Days)
- SLG 790.8K
- ICUI 277.5K
- Earning Date
- SLG 04-16-2025
- ICUI 05-06-2025
- Dividend Yield
- SLG 5.45%
- ICUI N/A
- EPS Growth
- SLG N/A
- ICUI N/A
- EPS
- SLG 0.08
- ICUI N/A
- Revenue
- SLG $706,577,000.00
- ICUI $2,382,046,000.00
- Revenue This Year
- SLG N/A
- ICUI $0.21
- Revenue Next Year
- SLG $2.06
- ICUI $2.47
- P/E Ratio
- SLG $814.18
- ICUI N/A
- Revenue Growth
- SLG N/A
- ICUI 5.44
- 52 Week Low
- SLG $47.22
- ICUI $93.36
- 52 Week High
- SLG $82.81
- ICUI $196.26
- Technical
- Relative Strength Index (RSI)
- SLG 27.86
- ICUI 39.08
- Support Level
- SLG $59.42
- ICUI $126.95
- Resistance Level
- SLG $62.17
- ICUI $145.00
- Average True Range (ATR)
- SLG 2.12
- ICUI 8.70
- MACD
- SLG -0.68
- ICUI -0.79
- Stochastic Oscillator
- SLG 2.49
- ICUI 37.66
About SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 32 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.